Author
Listed:
- Laurence Buisseret
(Institut Jules Bordet)
- Delphine Loirat
(Institut Curie)
- Philippe Aftimos
(Institut Jules Bordet)
- Christian Maurer
(University of Cologne)
- Kevin Punie
(University Hospitals Leuven)
- Véronique Debien
(Institut Jules Bordet)
- Paulus Kristanto
(Institut Jules Bordet)
- Daniel Eiger
(Institut Jules Bordet)
- Anthony Goncalves
(Institut Paoli-Calmettes)
- François Ghiringhelli
(Centre Georges-François Leclerc)
- Donatienne Taylor
(CHU-UCL-Namur - Site Sainte-Elisabeth)
- Florent Clatot
(Centre Henri Becquerel)
- Tom Mooter
(GZA Ziekenhuizen Campus Sint-Augustinus)
- Jean-Marc Ferrero
(Centre Antoine Lacassagne)
- Hervé Bonnefoi
(Institut Bergonié)
- Jean-Luc Canon
(Grand Hôpital de Charleroi - Site Notre Dame)
- Francois P. Duhoux
(Cliniques Universitaires Saint-Luc (UCLouvain))
- Laura Mansi
(CHU Besançon - Hôpital Jean Minjoz)
- Renaud Poncin
(Clinique Saint-Pierre)
- Philippe Barthélémy
(Institut de Cancérologie Strasbourg Europe (ICANS))
- Nicolas Isambert
(CHU Poitiers)
- Zoë Denis
(Institut Jules Bordet)
- Xavier Catteau
(CurePath Laboratory (CHU Tivoli, CHIREC))
- Roberto Salgado
(GZA-ZNA Hospitals)
- Elisa Agostinetto
(Institut Jules Bordet)
- Evandro Azambuja
(Institut Jules Bordet)
- Françoise Rothé
(Institut Jules Bordet)
- Ligia Craciun
(Institut Jules Bordet)
- David Venet
(Institut Jules Bordet)
- Emanuela Romano
(PSL Research University)
- John Stagg
(Faculté de Pharmacie et Institut du Cancer de Montréal)
- Marianne Paesmans
(Institut Jules Bordet)
- Denis Larsimont
(Institut Jules Bordet)
- Christos Sotiriou
(Institut Jules Bordet)
- Michail Ignatiadis
(Institut Jules Bordet)
- Martine Piccart-Gebhart
(Institut Jules Bordet)
Abstract
No abstract is available for this item.
Suggested Citation
Laurence Buisseret & Delphine Loirat & Philippe Aftimos & Christian Maurer & Kevin Punie & Véronique Debien & Paulus Kristanto & Daniel Eiger & Anthony Goncalves & François Ghiringhelli & Donatienne T, 2023.
"Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized,"
Nature Communications, Nature, vol. 14(1), pages 1-1, December.
Handle:
RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-44071-8
DOI: 10.1038/s41467-023-44071-8
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-44071-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.